{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'CLINICAL TRIAL SUMMARY', 'COMPOUND: SAR407899', 'STUDY No.: ACT14656', 'TITLE', 'A randomized, double-blind, placebo-controlled parallel arm dose', 'titration study to assess the effects of SAR407899 in patients with', 'microvascular angina and/or persistent stable angina despite', 'angiographically successful percutaneous coronary intervention (PCI).', 'INVESTIGATORITRIAL LOCATION', 'Europe, Asia and US', 'PHASE OF DEVELOPMENT', 'Phase 2a', 'STUDY OBJECTIVE(S)', 'Primary objective:', 'Assess the effects of SAR407899 on coronary vasomotor', 'function using coronary flow reserve (CFR) in patients with', 'microvascular angina and/or persistent stable angina despite', 'angiographically successful PCI.', 'Secondary objectives:', 'Assess the effects of SAR407899 on quality of life using', 'SAQ-PL in patients with microvascular angina and/or', 'persistent stable angina despite angiographically successful', 'PCI.', 'Assess the safety of SAR407899 in patients with', 'microvascular angina and/or persistent stable angina despite', 'angiographically successful PCI with a focus on identified', 'risks such as hypotension and orthostatic hypotension.', 'Assess SAR407899 plasma concentrations in microvascular', 'angina patients and/or persistent stable angina despite', 'angiographically successful PCI.', 'STUDY DESIGN', 'A Phase 2a, multi-center, randomized with 1:1 ratio, double-blind,', 'placebo-controlled parallel group study with weekly titration up to', 'maintenance dose, based on individual patient tolerability, particularly', 'symptomatic or asymptomatic blood pressure (BP) decreases.', 'STUDY POPULATION', 'Male and female patients with microvascular angina and/or persistent', 'stable angina despite angiographically successful PCI.', 'Main selection criteria', 'Main Inclusion criteria:', 'Male or female patient not at childbearing potential', '>18 year-old or legal age of majority.', 'Female patient if she has undergone sterilization at least', '3 months earlier or is postmenopausal.', '-', 'Post-menopausal status is defined by having no', 'menses for 12 months without an alternative medical', 'cause.', '-', 'In females not treated with hormonal replacement', 'therapy (HRT), menopausal status is confirmed by a', 'high follicle stimulating hormone (FSH) level greater', 'than 40 IU/L.', '-', 'In females on HRT and whose menopausal status is in', 'doubt (ie, in women aged less than 45 years), a highly', 'effective contraception methods will be required.', 'Property of the Sanofi Group - strictly confidential', 'Page 3', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Contraception should be used during the whole study', 'and for at least seven days corresponding to time', 'needed to eliminate study treatment.', 'Symptomatic stable angina pectoris (typical or atypical', 'symptoms with an average of at least bi-weekly episodes', 'over the past month),', 'Patients with non-obstructive (<50% stenosis) coronary', 'arteries or intermediate stenosis (between 50 and 70%)', 'should have fractional flow reserve (FFR) >0.80 or', 'instantaneous wave-free ratio (iFR) >0.89 on angiogram', 'documented within the previous 24 months*. In patients with', 'stenting, a minimum diameter stenosis of <10% is required.', 'or', 'Coronary computed tomography angiography (CCTA) with', 'finding of non-obstructive coronary arteries within the past', '24 months* in patients without previous PCI.', '*Note: in cases of clinically suspected progression of', 'atherosclerosis as per the Investigator, a more contemporary', '(ie, 6 months) evidence should be provided.', 'or', 'CCTA performed during screening period, with finding of non-', 'obstructive coronary arteries, in patients diagnosed with MVA', 'and stable angina without previous PCI who did not have a', 'coronary angiogram or CCTA in the previous 24 months but', 'between 24 months to 5 years.', 'Baseline global CFR (measured during the study) assessed', 'by 13N-ammonia or 82Rubidium PET scan <2.0.', 'Main Exclusion criteria:', 'Esophageal dysmotility or esophagitis.', 'Any use of nitrates (except short-acting nitrates) and/or', 'dipyridamole and/or phosphodiesterase type 5 (PDE5)', 'inhibitors within one week prior to baseline PET scan or', 'anticipated to be used during the study.', 'Patients with acute coronary syndrome (ACS) [myocardial', 'infarction (MI) and/or unstable angina] in previous 3 months.', 'Unsuccessful or incomplete coronary revascularization with', 'residual obstructive stenosis or coronary artery disease', '(CAD) progression in native vessels as documented on', 'invasive coronary angiography (>50% stenosis) within', '24 months of enrollment.', 'Patients with history of coronary artery bypass grafting', '(CABG).', 'Percutaneous coronary intervention performed at the time of', 'an ACS (MI or unstable angina) in the previous 12 months.', 'Recent PCI within the past 3 months.', 'Contraindication to vasodilator stress PET scan and/or CCTA', 'if CCTA needed during screening.', 'Regional local flow abnormal perfusion defects at baseline', 'PET scan*.', '*Note: if contemporary evidence with invasive coronary', 'Property of the Sanofi Group - strictly confidential', 'Page 4', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}